Press Release April 8, 2014

Home About the Pancreatic Cancer Action Network News / Press Center 2014 Press Releases Press Release April 8, 2014

April 8, 2014

FOR IMMEDIATE RELEASE

Nearly $5 Million in Research Grants Awarded for Innovative Pancreatic Cancer Research
 

SAN DIEGO — The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) awarded 14 grants through the 2014 Research Grants Program here today to outstanding scientists throughout the country, supporting their innovative research in the field of pancreatic cancer.

The grants support research into high-priority areas in an effort to reach the Pancreatic Cancer Action Network’s goal to double pancreatic cancer survival by 2020. Pancreatic cancer has historically been understudied and underfunded, yet it is the fourth leading cause of cancer death in the United States, and has the lowest survival rate of major cancers, at just 6 percent.

The diverse research topics funded this year include determining whether sudden-onset diabetes could be an early indicator of pancreatic cancer, strategies to starve pancreatic cancer cells of necessary nutrients, and a treatment method that involves harnessing the patient’s immune system to fight the tumor.

“Pancreatic cancer is among the most deadly of cancers,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “With death rates steadily climbing over the past decade, more research into pancreatic cancer is urgently needed. The AACR is, therefore, proud to be partnering with the Pancreatic Cancer Action Network to support cutting-edge scientific research projects that have the potential to lead to major breakthroughs in the prevention, detection, and treatment of this devastating disease.”

”The most promising science has been selected for funding through a rigorous peer-review process. This year’s grant recipients hail from leading institutions throughout the country and range from early career investigators continuing to build the field of pancreatic cancer leaders to more senior scientists,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “Their collective efforts have the potential to answer important questions that could lead to significant scientific advances for pancreatic cancer, and ultimately improve patient outcomes. We look forward to working with our new grantees and welcoming them to our team.”

The Pancreatic Cancer Action Network, in collaboration with the AACR, introduced the grants program in 2003, and has since awarded 108 research grants totaling more than $22 million to bright and motivated scientists across the country with the goals of developing a pipeline of researchers dedicated to studying the disease, supporting innovative ideas and approaches, and enabling the organization to reach its 2020 goal.

This year’s recipients will be honored today at the AACR Annual Meeting 2014, held April 5-9.

Meet the grant recipients and learn more about their funded projects.

The 2014 Pancreatic Cancer Action Network-AACR Research Acceleration Network Grants are three-year grants totaling $1 million each. These grants offer strategic funding and project management services to high-priority projects already underway within the pancreatic cancer research community. This year’s recipients are:

  • Giulio F. Draetta, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, Houston, Texas; and, Co-PI, Lewis C. Cantley, Ph.D., Weill Cornell Medical College, New York, N.Y.
    “Developing a novel oxidative phosphorylation inhibitor in pancreatic cancer”
  • Dung T. Le, M.D., Johns Hopkins Kimmel Cancer Center, Baltimore, Md.; and, Co-PI, Todd S. Crocenzi, M.D., Providence Portland Medical Center, Portland, Ore.
    “GVAX + CRS-207 heterologous prime boost vaccination with PD-1 blockade”
    Supported by the Fredman Family Foundation

The 2014 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant is a five-year grant totaling $600,000. This grant is designed to support the future leadership of pancreatic cancer research by funding an outstanding early-career investigator beginning a postdoctoral, mentored research position and continuing through a successful transition to independence. This year’s recipient is:

  • Gina M. DeNicola, Ph.D., Weill Cornell Medical College, New York, N.Y.
    “Therapeutic targeting of NRF2-regulated metabolism in pancreatic cancer”

The 2014 Pancreatic Cancer Action Network-AACR Innovative Grants are intended to promote the development and study of novel ideas and approaches in basic, translational, clinical, or epidemiological research that have direct application and relevance to pancreatic cancer. These two-year grants provide $200,000 over the grant term. This year’s recipients are:

  • Michael Thomas Barrett, Ph.D., Translational Genomics Research Institute, Scottsdale, Ariz.
    “Genomic drivers of therapeutic responses in metastatic disease”
  • Dafna Bar-Sagi, Ph.D., New York University School of Medicine New York, N.Y.
    “PDA development: Heads or tails?”
  • Anirban Maitra, MBBS, The University of Texas MD Anderson Cancer Center, Houston, Texas
    “Macrophage function in pancreatic cancer-associated diabetes”
  • George Miller, M.D., New York University School of Medicine, New York, N.Y. “Regulation of pancreatic tumorigenesis by necroptosis”
    Supported by Celgene Corporation
  • Diane M. Simeone, M.D., University of Michigan Medical Center, Ann Arbor, Mich.
    “Mesenchymal stem cells in pancreatic cancer biology and therapeutic development”

The 2014 Pancreatic Cancer Action Network-AACR Career Development Awards are two-year grants of $200,000 that are designed to attract and support early-career scientists as they conduct pancreatic cancer research and establish successful career paths in the field. This year’s recipients are:

  • David G. DeNardo, Ph.D., Washington University in St. Louis, St. Louis, Mo.
    “Origins and impact of macrophages in pancreatic cancer”
  • Eugene J. Koay, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, Houston, Texas
    “Changes in mass transport as a biomarker of response in pancreatic cancer”
  • Florencia McAllister, M.D., The University of Texas MD Anderson Cancer Center, Houston, Texas
    “Targeting IL-17 signaling axis in pancreatic ductal adenocarcinoma”
  • Kenneth L. Scott, Ph.D., Baylor College of Medicine, Houston, Texas
    “Functionalizing metabolic pathway driver aberrations in pancreatic cancer”
  • Kathryn E. Wellen, Ph.D., University of Pennsylvania, Philadelphia, Pa.
    “Understanding metabolic control of the pancreatic cancer epigenome”

The 2014 Pancreatic Cancer Action Network-AACR Fellowship is a one-year grant of $45,000 designed to support a postdoctoral investigator’s work in pancreatic cancer research. This year’s recipient is:

  • Barbara M. Grüner, Ph.D., Stanford University, Stanford, Calif.
    “Multiplexed in vivo drug screening: Inhibitors of metastatic seeding”
    Supported in memory of Samuel Stroum

Follow the AACR Annual Meeting 2014 on Twitter: #AACR14

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org. Follow the AACR Twitter: @AACR. Follow the AACR on Facebook: http://www.facebook.com/aacr.org.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative—The Vision of Progress: Double  Pancreatic Cancer Survival by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival. For more information, go to www.pancan.org.
Follow the Pancreatic Cancer Action Network on Twitter: @pancan
Follow the Pancreatic Cancer Action Network on Facebook: www.facebook.com/jointhefight

# # #

MEDIA INQUIRIES ONLY CONTACT:

Lauren Riley
American Association for Cancer Research
215-446-7155
lauren.riley@aacr.org

Jennifer Rosen
Senior Manager, Public Relations
Pancreatic Cancer Action Network
Direct: 310-706-3362
jrosen@pancan.org

ALL OTHER INQUIRIES, PLEASE CALL THE PANCREATIC CANCER ACTION NETWORK AT 877-272-6226 OR EMAIL INFO@PANCAN.ORG.

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.






Gear, apparel, accessories and more to show off your purple pride.


Shop Now 

©2018 Pancreatic Cancer Action Network. All rights reserved.


Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision PromiseSM and Demand Better For Patients. For Survival.SM are the trademarks of the Pancreatic Cancer Action Network, Inc.


The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.